- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic kidney disease
- Meeting Date: September 2021
- Public Summary Document (PSD) September 2021 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) September 2021 PBAC Meeting - (Word 356KB)
Dapagliflozin – September 2021
Dapagliflozin (chronic kidney disease): Tablet 10 mg; Forxiga®
Last updated
4 March 2022